Welcome to: Rimonabant Information Source (effects rimonabant side)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

HDL cholesterol increased by 28. 2%, compared with 16. 8% with placebo. Triglycerides decreased by an average of 8. 8% with rimonabant while rising 6. 3% in the placebo group. Rimonabant also significantly improved insulin sensitivity. Only about half of the observed improvement of lipids can be explained by the weight loss, implying that rimonabant exerts direct metabolic effects beyond weight loss, Dr. Van Gaal continued. As was the case after 1 year, rimonabant resulted in no significant changes in heart rate, blood pressure, or QT interval on the 2-year mark. The most common treatment side effects were nausea and other GI symptoms and dizziness, all of which were more in year 1 and mostly mild. Discus Sant Julius M. Gardin, MD, called RIO-Europe ", a remarkable study - really a landmark study in the field of obesity." He stressed that the 57% decline in the prevalence of metabolic syndrome as particularly impressive in terms of future cases of heart disease and diabetes prevention.

Rimonabant Pricelist

Please wait while we load the price list
They said the drug was safe, that people who stayed on the drug -- and on diet with a moderate reduction in calories -- lost 17 pounds. Their waists shrank by 3 inches. And they doubled their odds of quitting smoking. Now the first of these clinical trials is seeing the light of day. In a report to this week's 86th annual meeting of the Endocrine Society in New Orleans, F. Xavier Pi-Sunyer, MD, MPH, reported on 287 obese people who took rimonabant for 16 weeks. Pi-Sunyer is director of the obesity research center, director of the Joslin center for diabetes, and chief of endocrinology, diabetes, and nutrition at St. Luke's-Roosevelt Hospital Center."Our findings demonstrate that rimonabant is a safe and effective treatment for obesity," Pi-Sunyer said in a news release."These findings may help provide an option for the growing number of people who suffer from obesity, but do not respond to traditional weight-loss options such as diet and exercise.

This success of Rimonabant is the result of the benefits which it has given to numerous obese individuals in the European countries. After the UK, presently several other European countries are taking the benefits of Acomplia. Germany, Norway, Denmark, Ireland, Finland and Austria are those European nations where Sanofi-Aventis has already launched the sale of Rimonabant pills. Rimonabant blocks the working of cannabinoid receptor type-1. This function of Rimonabant pill has great significance in control of appetite. Cannabinoid type-1 (CB-1) receptors are the messengers of coordination system of the human body. Their working enables the brain to know about various requirements of cells.